2023-07-16-世界卫生组织-Immunization_Sudan_the_2023_country_profile_19页_378kb

报告摘要

Document: WHO and UNICEF estimates of national immunization coverage for Sudan.
Date: July 1, 2023
Next Revision: July 15, 2024
Data Received As Of: June 26, 2023

Estimated coverage represents the percentage of infants receiving recommended doses.

Bacillus Calmette-Guérin (BCG) Vaccine:

Coverage estimates are generally high, though recent (2019-Present) are based on extrapolation or challenged data. The 2013 estimate (93%) was supported by survey data indicating 85%. From 2011 onwards, estimates ranged between 87-93%.
GoC ••• (Well Supported) for 2013, •••/•/• for other years indicating varying data support.

Diphtheria-Tetanus-Pertussis (DTP) Vaccine (DTP3, DTP1):

Estimates for DTP3 peaked at over 97% (though often revised down from reported data exceeding 100%) in 2014-2015, dropping to around 90% by 2019, and remaining around 84-94% (challenged) or unavailable for 2020-2022.
GoC ••• for 2013, •• for many years, • for extrapolated years.

Measles Containing Vaccine (MCV1):

Coverage stayed relatively high from about 84% in the early 2017-2018 period, dropping slightly to 81% in 2021, remaining at 81% in 2022. Earlier years (2011-2016) were generally between 81-87%.
GoC varied, ••• around 2013, •/NA elsewhere.

Measles Containing Vaccine (MCV2):

Introduction in 2012 saw low initial coverage (24%). Coverage increased through 2015-2018 to reach high levels (>80%) around 2015-2018, with later estimates for 2019-2022 unavailable or challenged (Challenged/D-, GoC=NA).
GoC •/NA for most available years.

Polio Containing Vaccine (Pol3):

Similar to MCV1/DTP3, coverage was high and stable around 93-94% for several years (2013-2018), noted slight declines or variability in later years, remaining available around 85%. Available for 2011 onwards.
GoC ••• for 2013, •/NA elsewhere.

Hepatitis B Vaccine (HepB1/Birth Dose):

Hepatitis B Vaccine (HepB3):

Similar to Pol3/MCV1/DTP3, coverage was generally high and stable around 80-94% for the period 2011-Present, remaining around 84-84% for recent years as of available data.
GoC •••/•/NA.

Haemophilus influenzae type b vaccine (Hib3):

Unavailable estimates for most recent years (2019-Present). Data going back only to 2013 indicated ~90% coverage by 2015.
GoC Mostly Not Available (NA).

Rotavirus Vaccine (RotaC):

Introduced in 2011. Coverage reached ~64% in 2011 (42% of population) but saw significant fluctuations afterward, ranging from 27-95% in years with available data.
GoC D+/•/NA.

Pneumococcal Conjugate Vaccine (PcV3):

Introduced in 2013. Coverage increased from 30% in its first year, reaching >90% (though rare) or better in many later years (85% in 2022).
GoC NA for earlier years, •/••/NA for later.

Estimates Based On: Data are sourced from national administrative reports, surveys, or extrapolated. Quality varies.
GoC Meaning: Reflects the degree of empirical support, not the absolute quality of national data.
Stockouts: Vaccination stockouts or supply disruptions were noted to affect DTP1, DTP3, MCV1, and Pol3 estimates in specific years.
Survey Data: Results from the 2014 and 2009/2010 surveys are mentioned but often down-weighted or assigned specific GoC exceptions due to concerns about documentation.
Next Steps: Upcoming data from the 2023 Multiple Indicator Cluster Survey will affect estimates presented in the next revision (July 15, 2024).